Pharmaceuticals

Biomarkers Market 2026–2030: Forecast, Innovation, and Competitive Trends

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biomarkers market from 2026–2035 with trusted insights from The Business Research Company

How much is the Biomarkers Market valued at in 2026, and what valuation is forecast for 2030?

The biomarkers market has seen rapid expansion in recent years. Its value is anticipated to rise from $77.42 billion in 2025 to $88.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. The factors contributing to its past growth include advancements in molecular biology, increased spending on pharmaceutical research and development, a rising prevalence of cancer, more extensive use in clinical trials, and the demand for targeted therapies.

The biomarkers market is projected to experience substantial expansion over the coming years, with its size set to reach $150.52 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.2%. This anticipated growth is largely due to factors such as the broadening of personalized treatment strategies, increasing acceptance of liquid biopsy biomarkers, enhanced regulatory backing for biomarker-centric medications, advancements in neurological disease studies, and growing partnerships between pharmaceutical and diagnostic companies. Key developments expected during this period involve the rising application of biomarkers in precision medicine, their deeper integration into drug discovery and development processes, wider usage in managing oncology and chronic diseases, the proliferation of companion diagnostics, and a heightened emphasis on identifying diseases early.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Drivers Are Influencing The Growth Of The Biomarkers Market?

The rising incidence of heart diseases is projected to drive the expansion of the biomarkers market during the forecast period. Over recent years, there has been a significant surge in the application of biomarkers for individuals suffering from heart conditions. Presently, natriuretic peptides stand as the most frequently utilized biomarker, aiding in the diagnosis of heart failure patients. For heart failure diagnosis, biomarkers like circulating biomarkers with high sensitivity C-reactive protein are employed. In the United States, heart disease ranks among the primary causes of mortality across most racial and ethnic demographics. Consequently, the growing prevalence of heart diseases will fuel the demand for biomarkers. As an illustration, data from September 2025, provided by the British Heart Foundation, a UK-based charity, reveals that over 7.6 million people in the UK (comprising more than 4 million men and over 3.6 million women) are currently affected by cardiovascular disease. Furthermore, projections suggest that this figure could increase by approximately 1 million by 2030 and by roughly 2 million by 2040, influenced by an aging populace and better survival rates. This sustained increase in heart diseases is thus accelerating the growth of the biomarkers market.

How Is The Biomarkers Market Organized Into Various Segments?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Which Competitive Trends Are Impacting The Structure Of The Biomarkers Market?

Major companies active in the biomarker market are creating advanced products, such as biomarker tests, to attract larger customer bases, boost sales, and increase revenue. Biomarker tests, also known as biomarker assays, are laboratory or diagnostic techniques that measure specific biological markers, including molecules, genes, proteins, or other substances, to provide information about various physiological or pathological processes within the body. For instance, in July 2023, Quest Diagnostics, a US-based medical laboratories company, launched a novel prostate cancer biomarker test. This newly introduced tissue-based test service aims to fulfill the urgent clinical need for tests capable of distinguishing potentially aggressive cases of prostate cancer in males. Quest developed and validated this laboratory test through an intellectual property license agreement with Envision, allowing the utilization of Envision’s exclusive biomarker and immunohistochemistry technology, incorporating Envision’s distinct staining methods and innovative biomarkers referred to as EV1, EV2, and EV3.

Who Are The Top-Performing Companies In The Biomarkers Market In Recent Years?

Major companies operating in the biomarkers market are Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Currently Holds The Largest Share Of The Biomarkers Market?

North America was the largest region in the biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795